The global burden of mental and substance use disorders: changes in estimating burden between GBD1990 and GBD2010. (23rd April 2014)

• Record Type: Journal Article
• Authors: Baxter, A. J.; Ferrari, A. J.; Erskine, H. E.; Charlson, F. J.; Degenhardt, L.; Whiteford, H. A.
• Is Part Of: Epidemiology and psychiatric sciences. Volume 23:Number 3(2014)
• Page Start: 239
• Page End: 249
• Publication Date: 2014-04-23
• Subjects: global burden of disease, -- health metrics, -- mental disorders, -- public health; Epidemiology -- Periodicals; Mental illness -- Periodicals; Community psychiatry -- Periodicals; 362.2
• DOI: 10.1017/S2045796014000237
• Languages: English
• ISSNs: 2045-7960

Abstract

Abstract : Background: The main aim of this paper is to compare and contrast the methodological approaches of the new Global Burden of Disease 2010 Study (GBD 2010) with the original study conducted for 1990 (GBD 1990), in terms of calculating burden for mental and substance use disorders. Methods: We reviewed the conceptual and methodological changes to GBD burden calculations in the GBD 2010 study, compared with previous studies. We then discuss the possible implications of these changes with respect to burden estimates for mental and substance use disorders. Results: It is not possible to compare burden estimates arising from the GBD 1990 study with the most recent burden estimates. There have been important advances in the categorisation and definition of mental disorders, and the input and computation of epidemiological models for disease distribution. There have also been major changes to conceptual and social value choices aimed at addressing concerns that arose following publication of earlier GBD studies. Conclusion: Advancements to the GBD conceptual framework and method of calculating burden estimates has led to more accurate and equitable consideration of the burden for mental and substance use disorders. Proposed annual updates of GBD estimates by the Institute of Health Metrics and Evaluation provide an opportunity to continue to advance the evidence base that underpins the quantification of disease burden.